Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 × 2 factorial, randomized, placebo‐controlled trial
Addiction2023Vol. 118(9), pp. 1710–1725
Citations Over TimeTop 14% of 2023 papers
Brian Hitsman, George D. Papandonatos, Jackie K. Gollan, Mark D. Huffman, Raymond Niaura, David C. Mohr, Anna Veluz‐Wilkins, Su Fen Lubitz, Anita Hole, Frank T. Leone, Sadiya S. Khan, Erica Fox, Anna‐Marika Bauer, E. Paul Wileyto, Joseph Bastian, Robert A. Schnoll
Abstract
A randomized trial in smokers with major depressive disorder found that varenicline improved smoking abstinence versus placebo at 27 weeks without elevating rates of adverse events. Behavioral activation for smoking cessation did not outperform standard behavioral treatment, with or without adjunctive varenicline therapy.
Related Papers
- → Smoking cessation therapy with varenicline(2008)27 cited
- → Smoking cessation treatment for COPD smokers: the role of pharmacological interventions(2015)11 cited
- → Adherence to Varenicline and Abstinence Rates for Quitting Smoking in a Private Health Promotion Center-Based Smoking Cessation Clinic(2012)9 cited
- → A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline(2010)3 cited
- → Pharmacotherapy guidelines for smoking cessation in primary healthcare clinics(2024)2 cited